Weekly epirubicin in the treatment of gestational breast cancer (GBC)
- 247 Downloads
Background GBC is a rare disease and chemotherapy in this setting lacks a standardized approach. Patients and Methods Patients 16–30 weeks pregnant with locally advanced/metastatic disease or with high risk of recurrence after surgery were evaluated. Results Twenty patients received weekly epirubicin 35 mg/m2. Median maternal age was 37 years (23–42). Median gestational age at chemotherapy was 19 weeks. Thirteen patients were treated after surgery while 7 had locally advanced tumours of which one had liver metastases. Mean total epirubicin dose was 420 mg/m2 with a median number of 12 administrations (4–16). No grade 3–4 toxicities were observed. No foetal adverse events were observed except 1 premature delivery at 28 weeks. Births were induced by caesarean section in 12 patients at a median gestational age of 35 weeks. No malformations were reported except 1 newborn with polycystic kidney. At a median age of 2 years, neurological, cardiological and immunological development was normal in all children as reported by their parents. In 7/20 patients with evaluable disease, five had an objective response. At a median follow-up of 38 months, 17 patients are alive; 14 are disease free. Conclusions Weekly epirubicin appears safe and effective with low foetal toxicity and could be considered in GBC.
KeywordsBreast cancer Pregnancy Epirubicin Chemotherapy Safety Foetus
- 2.Berkowitz GS, Skovron ML, Lapinski RH, Berkowitz RL (1990) Delayed childbearing and the outcome of pregnancy. N Engl J Med 322:639–664Google Scholar
- 5.Boldrini R, Di Cesare M, Tamburini C (eds) (2007) Rapporto CeDAP, 2004. Italian Ministry of Health website (www.ministerosalute.it)
- 16.Myers C (1988) Role of iron in anthracycline action. In: Hacker M, Lazo J, Tritton T (eds) Organ directed toxicities of anticancer drugs. Martinus Nijhoff, Boston, Mass, pp 17–30Google Scholar